Bristol Myers Squibb on Thursday reported a first-quarter loss as charges related to its recent acquisitions of Karuna Therapeutics, RayzeBio and Mirati Therapeutics offset a 5% increase in revenue.
The New Jersey-based drugmaker posted a loss of $4.40 per share, including charges for acquired research and development. Analysts on average had expected a loss of $4.41 per…

#bristolmyerssquibb#karunatherapeutics#rayzebio#miratitherapeutics#newjersey#bristol#pfizer#opdualag